Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease1 New results show...
Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer...
Post-progression outcomes showed significant and sustained improvement for amivantamab plus chemotherapy versus chemotherapy alone1 BEERSE, BELGIUM , Sept. 14, 2024...
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the...
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at...
MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug...
CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced...
Toronto, Ontario--(Newsfile Corp. - September 13, 2024) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K9) ("Quantum BioPharma" or...
Before the start of the ESMO congress, MEDSIR has brought together scientists, researchers, pharmaceutical companies, and patient association representatives to...
SHANGHAI, Sept. 13, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company...
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune...
Webcast replay of fireside chat now available ISELIN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK),...
- New CFO Brings Multiple Years of Experience from Biotech Companies- As Part of the New Hire, the Company Issues...
BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
As the stage is set for another year of groundbreaking research and transformative treatment advancements, several companies are seizing the...
Cellares and Sony will collaborate on integrating Sony's cell sorting and analytical technologies into the Cell Shuttle, Cellares' automated cell...
Company Leverages Causal Machine Learning to Overcome Key Challenges in Developing New Cancer Treatments BOSTON, Sept. 12, 2024 /PRNewswire/ --...
CAMBRIDGE, England, Sept. 12, 2024 /PRNewswire/ -- Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring...
STOCKHOLM, Sept. 12, 2024 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to...
HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...